Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2017 Dec 5

PMID 29201076

Citations 3

Authors

Mohammad Mehdi Mahboobian

Ali Seyfoddin

Ilva D Rupenthal

Reza Aboofazeli

Seyed Mohsen Foroutan

Affiliations

Soon will be listed here.

Abstract

Brinzolamide (BZ) is an intraocular pressure reducing agent with low bioavailability. The purpose of the present study was to overcome this issue by development of BZ containing nanoemulsions (NEs) as an ocular drug delivery system with desirable therapeutic efficacy. Brinzolamide NEs were prepared by the spontaneous emulsification method. Based on initial release studies, twelve formulations with the slowest release characteristics were subjected to further physicochemical investigations such as particle size, polydispersity index, pH, refractive index, osmolality and viscosity. The therapeutic efficacy of these formulations was assessed by measuring the intraocular pressure after instillation of the prepared NEs in normotensive albino rabbit eyes. Nanoemulsions with suitable physicochemical properties exhibited high formulation stability under different conditions. more over biological evaluations indicated that using lower drug concentrations in NE formulations (0.4%) had a similar or even better pharmacodynamic effect compared to the commercial suspension with a higher drug concentration (1%). Our findings suggest that NEs could be effectively used as carriers for enhancing the bioavailability of topically applied ophthalmic drugs.

Citing Articles

Development of Self-Assembling -1,4-Dihydropyridines: Detailed Studies of Bromination of Four Methyl Groups and Bromine Nucleophilic Substitution.

Kaukulis M, Rucins M, Lacis D, Plotniece A, Sobolev A Molecules. 2024; 29(1).

PMID: 38202746 PMC: 10779897. DOI: 10.3390/molecules29010161.

Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation.

Kassaee S, Mahboobian M Drug Deliv Transl Res. 2021; 12(1):229-239.

PMID: 33575973 DOI: 10.1007/s13346-021-00902-z.

Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.

Occhiutto M, Maranhao R, Costa V, Konstas A Adv Ther. 2019; 37(1):155-199.

PMID: 31823205 PMC: 6979457. DOI: 10.1007/s12325-019-01163-6.

References

Silver L . Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000; 44 Suppl 2:S141-5. DOI: 10.1016/s0039-6257(99)00111-3. View

Ngawhirunpat T, Worachun N, Opanasopit P, Rojanarata T, Panomsuk S . Cremophor RH40-PEG 400 microemulsions as transdermal drug delivery carrier for ketoprofen. Pharm Dev Technol. 2011; 18(4):798-803. DOI: 10.3109/10837450.2011.627871. View

Badawi A, El-Laithy H, El Qidra R, El Mofty H, El dally M . Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008; 31(8):1040-9. DOI: 10.1007/s12272-001-1266-6. View

Wu C, Qi H, Chen W, Huang C, Su C, Li W . Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi. 2007; 127(1):183-91. DOI: 10.1248/yakushi.127.183. View

Bourlais C, Acar L, Zia H, Sado P, Needham T, LEVERGE R . Ophthalmic drug delivery systems--recent advances. Prog Retin Eye Res. 1998; 17(1):33-58. DOI: 10.1016/s1350-9462(97)00002-5. View

Ammar H, Salama H, Ghorab M, Mahmoud A . Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009; 10(3):808-19. PMC: 2802135. DOI: 10.1208/s12249-009-9268-4. View

Mainardes R, Urban M, Cinto P, Khalil N, Chaud M, Evangelista R . Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets. 2005; 6(3):363-71. DOI: 10.2174/1389450053765914. View

El-Kamel A . In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm. 2002; 241(1):47-55. DOI: 10.1016/s0378-5173(02)00234-x. View

Gaudana R, Jwala J, Boddu S, Mitra A . Recent perspectives in ocular drug delivery. Pharm Res. 2008; 26(5):1197-216. PMC: 4516219. DOI: 10.1007/s11095-008-9694-0. View

10.

Urtti A . Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006; 58(11):1131-5. DOI: 10.1016/j.addr.2006.07.027. View

11.

Sakulku U, Nuchuchua O, Uawongyart N, Puttipipatkhachorn S, Soottitantawat A, Ruktanonchai U . Characterization and mosquito repellent activity of citronella oil nanoemulsion. Int J Pharm. 2009; 372(1-2):105-11. DOI: 10.1016/j.ijpharm.2008.12.029. View

12.

Fialho S, Da Silva-Cunha A . New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exp Ophthalmol. 2004; 32(6):626-32. DOI: 10.1111/j.1442-9071.2004.00914.x. View

13.

Kaur I, Smitha R . Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002; 28(4):353-69. DOI: 10.1081/ddc-120002997. View

14.

Shafiq S, Shakeel F, Talegaonkar S, Ahmad F, Khar R, Ali M . Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2006; 66(2):227-43. DOI: 10.1016/j.ejpb.2006.10.014. View

15.

Tayel S, El-Nabarawi M, Tadros M, Abd-Elsalam W . Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm. 2013; 443(1-2):293-305. DOI: 10.1016/j.ijpharm.2012.12.049. View

16.

Gaudana R, Krishna Ananthula H, Parenky A, Mitra A . Ocular drug delivery. AAPS J. 2010; 12(3):348-60. PMC: 2895432. DOI: 10.1208/s12248-010-9183-3. View

17.

Calvo P, Alonso M, Robinson J . Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol. 1996; 48(11):1147-52. DOI: 10.1111/j.2042-7158.1996.tb03911.x. View

18.

Chen H, Khemtong C, Yang X, Chang X, Gao J . Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2010; 16(7-8):354-60. DOI: 10.1016/j.drudis.2010.02.009. View

19.

Morrison P, Khutoryanskiy V . Advances in ophthalmic drug delivery. Ther Deliv. 2014; 5(12):1297-315. DOI: 10.4155/tde.14.75. View

20.

Kesavan K, Pandit J, Kant S, Muthu M . Positively charged microemulsions of dexamethasone: comparative effects of two cosurfactants on ocular drug delivery and bioavailability. Ther Deliv. 2013; 4(11):1385-95. DOI: 10.4155/tde.13.106. View